Emocha Pitch Deck: Slide-by-Slide Breakdown

Executive Summary and The 'Why'

Emocha Health’s pitch deck is a masterclass in clinical positioning. Rather than leading with market size or revenue growth, they lead with institutional credibility and a specific, high-stakes medical problem. As a Johns Hopkins spin-out, the company leverages its academic roots to frame medication adherence not just as a behavioral issue, but as a critical clinical failure point with massive economic consequences.

Slide 1: Title Slide

The deck opens with the tagline "Support every patient at every dose." The imagery shows a healthcare provider interacting with a patient, emphasizing the human element of their digital solution. Contact information and social handles are clearly displayed at the bottom.

Slide 2: The Snapshot

This is a high-impact credibility slide. It establishes four key pillars: Emocha is the standard of care for 450 health departments, is validated by 15 peer-reviewed studies, is a Johns Hopkins spin-out, and has a 50-person team consisting of nurses, pharmacists, and public health technologists. This immediately answers the 'why you' question for an investor.

Slide 3: The Definition

Emocha defines itself as the first comprehensive "Digital Medication Adherence Program." They use a simple Venn diagram to show the intersection of Video Technology and Human Engagement. A footnote mentions their model leverages a CDC-endorsed public health practice.

Slide 4: Possession vs. Ingestion

This is the most important conceptual slide in the deck. It challenges the industry standard "Medication Possession Ratio" (MPR). Emocha argues that just because a patient has the pills (possession) doesn't mean they are taking them (ingestion). They position their video observation as the only way to truly measure adherence.

Slide 5 & 6: The Transplant Problem

These slides narrow the focus to transplant patients. Slide 5 notes that non-adherence ranges from 20% to 70% in this group. Slide 6 provides the 'so what': 40% of rejections are linked to non-adherence, and hospitalization costs for these episodes range from $4,000 to $11,000. This builds the ROI case for payers and providers.

Slide 7: The Complexity of Challenges

A Venn diagram illustrates that post-transplant patients face a mix of Medication Problems (dosing, side effects), Social Determinants of Health (transportation, costs), and Human Behavior/Biases (forgetfulness, information avoidance). This slide justifies why a simple 'reminder app' isn't enough and why Emocha’s multi-faceted approach is necessary.

Slide 8: The Program Workflow

This slide visualizes the journey: a Pharmacist-led medication review, followed by 3 months of Daily Directly Observed Therapy (video), leading into ongoing support. It shows the faces of the pharmacist, coach, and nurse to reinforce the human-led nature of the tech.

Slide 9: Platform & Service Overview

This slide breaks down the three-sided nature of the platform: the Patient (mobile app), the Adherence Service (clinical team), and the Transplant Team (analytics and reporting). It shows the UI for both the mobile app and the clinical dashboard.

Slide 10: Patient-facing Mobile App

A detailed look at the app features. Key callouts include: Medication reminders, symptom capture, asynchronous and live video, in-app messaging, financial incentives, and support for 22 languages. The UI looks clean and modern, mimicking standard social video interfaces.

Slide 11: The Transitional Care Team

This slide details the roles of the human staff. Pharmacists handle reconciliation and education; Adherence Coaches review video check-ins and provide motivation; Registered Nurses provide clinical review of symptoms and liaise with the patient’s primary care team.

Slide 12: Clinical Evidence

This is a data-heavy proof slide. It shows adherence rates across different diseases: Tuberculosis (92-95%), Hepatitis C (98%), and Asthma (92%). It also notes a 73% reduction in ED visits for Asthma patients and a 50% reduction for Type 2 Diabetes patients. The logos of the NIH and CDC are used to anchor these results.

Slide 13: References

A rare but welcome slide in a startup deck. Emocha lists four specific academic citations from PubMed and NCBI to back up the statistics used in the previous slides. This reinforces the 'clinical-first' brand identity.

Slide 14: Reiteration of Vision

A repeat of the title slide imagery, serving as a transition to the final section of the deck.

Slide 15: Transplant Opportunities & Program Value

This slide summarizes the value proposition: minimizing avoidable costs, decreasing rejection likelihood, protecting the 'second chance at life,' and streamlining care coordination.

Slide 16: Vision & Partners

The vision is stated as making technology-enabled directly observed therapy the standard of care. The right side of the slide lists prestigious partners, including Johns Hopkins University, University of Virginia, and the National Institute of Diabetes and Digestive Kidney Diseases.

Slide 17: Analytics Dashboard

This slide shows actual data from a cohort of 75 patients. It highlights a 92% average adherence rate and shows that 6.8% of patients required escalation. The charts show 'Dose-Timeliness Adherence Trends' and a breakdown of 8,456 observed video check-ins. This proves the system is operational and generating actionable data.

Slide 18: Scalable Messaging Protocols

The final content slide shows the communication interface. It highlights 'suggested' messages for coaches (e.g., motivational, clinical issue, protocol issues), suggesting that Emocha has a playbook for patient interaction that goes beyond simple chatting.

What Works in This Deck

Clinical Credibility: The constant referencing of peer-reviewed studies and institutional partners makes the solution feel 'vetted' rather than just another health-tech experiment. · Problem Specificity: By focusing on transplant patients, they identify a high-cost, high-risk niche where the ROI of their intervention is easy to calculate. · Product Clarity: The distinction between 'possession' and 'ingestion' is a powerful way to frame their competitive advantage.

What Is Missing

Business Model: There is no mention of how Emocha makes money. Is it a per-patient-per-month fee? A percentage of cost savings? A licensing fee for the software? · Market Size: While they focus on transplants, they don't quantify the Total Addressable Market (TAM) or explain how they scale into other chronic conditions. · Financials and Ask: The deck lacks a slide on current revenue, burn rate, or the specific amount of capital they are looking to raise. · Competition: There is no mention of other adherence solutions (smart pill bottles, other video apps, or traditional pharmacy-led programs).

Founder Takeaways

Lead with evidence if you have it. If your startup is in a regulated or high-stakes industry like healthcare, your clinical data is more important than your UI. Emocha spends nearly half the deck proving their system works before they even show the app. Identify the 'Gap' in current metrics. Emocha’s best slide is the one that explains why the current industry standard (MPR) is flawed. If you can prove that the way your industry currently measures success is wrong, you create an immediate need for your solution. Human + Tech is a winning combo for services. Investors are often wary of pure service businesses because they don't scale, but they are also wary of pure tech in healthcare because patients need empathy. Emocha frames their human team as a 'Transitional Care Team' that 'amplifies' the tech, making it feel like a scalable hybrid model.